Courtney Rebecca Hamblyn Lynch

Dr. Courtney Rebecca Hamblyn Lynch

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
SJStephen M.F. Jamieson
Stephen M.F. Jamieson
PTPeter Tsai
Peter Tsai
MKMaria K. Kondratyev
Maria K. Kondratyev
PBPratha Budhani
Pratha Budhani
ALArthur Liu
Arthur Liu
FHFrancis W. Hunter
Francis W. Hunter
Evofosfamide (TH-302) is a clinical-stage hypoxia-activated prodrug of a DNA-crosslinking nitrogen mustard that has potential utility for human papillomavirus (HPV) negative head and neck squamous cell carcinoma (HNSCC), in which tumor hypoxia limits treatment outcome. We report the preclinical efficacy, target engagement, preliminary predictive biomarkers and initial clinical activity of evofosfamide for HPV-negative HNSCC. Evofosfamide was assessed in 22 genomically characterized cell lines and 7 cell line–derived xenograft (CDX), patient-derived xenograft (PDX), orthotopic, and syngeneic tumor models. Biomarker analysis used RNA sequencing, whole-exome sequencing, and whole-genome CRISPR knockout screens. Five advanced/metastatic HNSCC patients received evofosfamide monotherapy (480 mg/m 2 qw × 3 each month) in a phase 2 study. Evofosfamide was potent and highly selective for hypoxic HNSCC cells. Proliferative rate was a predominant evofosfamide sensitivity determinant and a proliferation metagene correlated with activity in CDX models. Evofosfamide showed efficacy as monotherapy and with radiotherapy in PDX models, augmented CTLA-4 blockade in syngeneic tumors, and reduced hypoxia in nodes disseminated from an orthotopic model. Of 5 advanced HNSCC patients treated with evofosfamide, 2 showed partial responses while 3 had stable disease. In conclusion, evofosfamide shows promising efficacy in aggressive HPV-negative HNSCC, with predictive biomarkers in development to support further clinical evaluation in this indication.

21 November 2020 in WIREs Forensic Science
Verified
Journal Article
Closed access
PDF file
CLCourtney Rebecca Hamblyn Lynch
Courtney Rebecca Hamblyn Lynch
RFRachel Fleming
Rachel Fleming

11 August 2017 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YGYongchuan Gu
Yongchuan Gu
TCTony T.-A. Chang
Tony T.-A. Chang
JWJingli Wang
Jingli Wang
JJJagdish K. Jaiswal
Jagdish K. Jaiswal
DEDavid Edwards
David Edwards
KHKevin O. Hicks
Kevin O. Hicks
3-(3-Morpholinopropyl)-7,8-dihydro-6H-indeno[5,6-e][1,2,4]triazine 1,4-dioxide (SN30000), an analogue of the well-studied bioreductive prodrug tirapazamine (TPZ), has improved activity against hypoxic cells in tumour xenografts. However, little is known about its biotransformation in normal tissues. Here, we evaluate implications of biotransformation of SN30000 for its toxicokinetics in NIH-III mice. The metabolite profile demonstrated reduction to the 1-N-oxide (M14), oxidation of the morpholine side-chain (predominantly to the alkanoic acid M18) and chromophore, and subsequent glucuronidation. Plasma pharmacokinetics of SN30000 and its reduced metabolites was unaffected by the presence of HT29 tumour xenografts, indicating extensive reduction in normal tissues. This bioreductive metabolism, as modelled by hepatic S9 preparations, was strongly inhibited by oxygen indicating that it proceeds via the one-electron (radical) intermediate previously implicated in induction of DNA double strand breaks and cytotoxicity by SN30000. Plasma pharmacokinetics of SN30000 and M14 (but not M18) corresponded closely to the timing of reversible acute clinical signs (reduced mobility) and marked hypothermia (rectal temperature drop of ~ 8oC at nadir following the maximum tolerated dose). Similar acute toxicity was elicited by dosing with TPZ or M14, although M14 did not induce the kidney and lung histopathology caused by SN30000. M14 also lacked antiproliferative potency in hypoxic cell cultures. In addition M14 showed much slower redox cycling than SN30000 in oxic cultures. Thus a non-bioreductive mechanism. mediated through M14, appears to be responsible for the acute toxicity of SN30000 while late toxicities are consistent with DNA damage resulting from its one-electron reduction. A two-compartment pharmacokinetic model, in which clearance of SN30000 is determined by temperature-dependent bioreductive metabolism to M14, was shown to describe the non-linear PK of SN30000 in mice. This study demonstrates the importance of non-tumour bioreductive metabolism in the toxicology and pharmacokinetics of benzotriazine di-oxides designed to target tumour hypoxia.

11 March 2023 in Forensic Science International: Genetics
Verified
Journal Article
Closed access
CLCourtney Rebecca Hamblyn Lynch
Courtney Rebecca Hamblyn Lynch
RFRachel Fleming
Rachel Fleming

31 March 2019 in WIREs Forensic Science
Verified
Journal Article
Open access
PDF file
CLCourtney Rebecca Hamblyn Lynch
Courtney Rebecca Hamblyn Lynch
RFRachel Fleming
Rachel Fleming
Short tandem repeat (STR) profiling is frequently carried out on biological stains in forensic casework, and the application of messenger RNA (mRNA) body fluid identification is becoming more prevalent. Increasing constraints on analysis time, resources, an increase in the number of samples for analysis, and a large backlog of cases creates significant demand for quicker methods that direct polymerase chain reaction (PCR) can help overcome. Direct PCR bypasses DNA and/or RNA extraction, and in some cases, quantification by adding the sample or substrate punch to the amplification reaction. This method is currently used in some laboratories on reference samples. Direct PCR is also a component of portable devices, which could improve efficiency even further by producing results at the scene, and enabling triaging of samples for further testing. Portable devices are currently used for STR profiling of reference samples but not for mRNA profiling. Various concerns regarding the reliability of the method and equipment (portable devices) must first be addressed before incorporation into forensic casework. This review discusses the limitations and factors that need to be considered for direct PCR to be used for the analysis of casework samples, including being used for mRNA body fluid identification.This article is categorized under: Forensic Biology > Forensic DNA Technologies Forensic Biology > Body Fluid Identification Forensic Biology > Applications of RNA

30 October 2024 in Forensic Science International: Genetics
Verified
Journal Article
Closed access
CLCourtney Rebecca Hamblyn Lynch
Courtney Rebecca Hamblyn Lynch
OMOlivia L. Martin
Olivia L. Martin
CBCraig Billington
Craig Billington
RFRachel Fleming
Rachel Fleming